このエントリーをはてなブックマークに追加
ID 62250
フルテキストURL
fulltext.pdf 3.08 MB
著者
Sakaida, Kyosuke Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Omori, Kazuhiro Department of Periodontics and Endodontics, Okayama University Hospital ORCID Kaken ID publons researchmap
Nakayama, Masaaki Department of Oral Microbiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Mandai, Hiroki Department of Pharmacy, Faculty of Pharmacy, Gifu University of Medical Science ORCID Kaken ID publons researchmap
Nakagawa, Saki Department of Periodontics and Endodontics, Okayama University Hospital
Sako, Hidefumi Department of Periodontics and Endodontics, Okayama University Hospital
Kamei, Chiaki Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Yamamoto, Satoshi Department of Periodontics and Endodontics, Okayama University Hospital
Kobayashi, Hiroya Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Ishii, Satoki Division of Applied Chemistry, Graduate School of Natural Sciences and Technology, Okayama University
Ono, Mitsuaki Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID researchmap
Ibaragi, Soichiro Department of Oral Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID publons researchmap
Yamashiro, Keisuke Department of Periodontics and Endodontics, Okayama University Hospital, Okayama, Japan, 3Department of Oral Microbiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID publons
Yamamoto, Tadashi Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID publons researchmap
Suga, Seiji Division of Applied Chemistry, Graduate School of Natural Sciences and Technology, Okayama University ORCID Kaken ID researchmap
Takashiba, Shogo Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID publons researchmap
抄録
Osteoporosis is a common disease characterized by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. Severe bone loss due to osteoporosis triggers pathological fractures and consequently decreases the daily life activity and quality of life. Therefore, prevention of osteoporosis has become an important issue to be addressed. We have reported that the fungal secondary metabolite (+)-terrein (TER), a natural compound derived from Aspergillus terreus, has shown receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclast differentiation by suppressing nuclear factor of activated T-cell 1 (NFATc1) expression, a master regulator of osteoclastogenesis. TER has been shown to possess extensive biological and pharmacological benefits; however, its effects on bone metabolism remain unclear. In this study, we investigated the effects of TER on the femoral bone metabolism using a mouse-ovariectomized osteoporosis model (OVX mice) and then on RANKL signal transduction using mouse bone marrow macrophages (mBMMs). In vivo administration of TER significantly improved bone density, bone mass, and trabecular number in OVX mice (p < 0.01). In addition, TER suppressed TRAP and cathepsin-K expression in the tissue sections of OVX mice (p < 0.01). In an in vitro study, TER suppressed RANKL-induced phosphorylation of PKC alpha/beta II, which is involved in the expression of NFATc1 (p < 0.05). The PKC inhibitor, GF109203X, also inhibited RANKL-induced osteoclastogenesis in mBMMs as well as TER. In addition, TER suppressed the expression of osteoclastogenesis-related genes, such as Ocstamp, Dcstamp, Calcr, Atp6v0d2, Oscar, and Itgb3 (p < 0.01). These results provide promising evidence for the potential therapeutic application of TER as a novel treatment compound against osteoporosis.
キーワード
(+)-terrein
ovariectomy
osteoporosis
RANKL
PKC
発行日
2021-06-08
出版物タイトル
Frontiers In Pharmacology
12巻
出版者
Frontiers Media SA
開始ページ
674366
ISSN
1663-9812
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2021 Sakaida, Omori, Nakayama, Mandai, Nakagawa, Sako, Kamei, Yamamoto, Kobayashi, Ishii, Ono, Ibaragi, Yamashiro, Yamamoto, Suga and Takashiba.
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.3389/fphar.2021.674366
ライセンス
https://creativecommons.org/licenses/by/4.0/
助成機関名
日本学術振興会
Wesco Scientific Promotion Foundation
助成番号
19K10108
20K18509